Ishara Investments LP — 13F Holdings & Portfolio
CIK 2111609 · latest 13F-HR filed 2026-05-15
Ishara Investments LP manages $105.6M in 13F-reported U.S. long-equity assets across 37 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PRAX (6.88%), AXSM (6.56%), PRAX (6.25%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 17 new positions, exited 18, added to 8, and trimmed 7.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$105.6M
Long-equity book
37
Distinct positions
2026-03-31
Filed 2026-05-15
+17 / −18 / ↑8 / ↓7
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ULTRAGENYX PHARMACEUTICAL IN$2.5M +217.4%
- VERASTEM INC$2.3M +108.5%
- ZENTALIS PHARMACEUTICALS INC$1.1M +61.5%
- VAXCYTE INC$1.0M +44.6%
- IMMATICS N.V$672.9K +80.1%
Top Trims
- PRAXIS PRECISION MEDICINES I-$4.5M -38.4%
- ANNEXON INC-$2.8M -74.4%
- PTC THERAPEUTICS INC-$2.0M -74.5%
- ACADIA PHARMACEUTICALS INC-$1.5M -35.9%
- BIOMARIN PHARMACEUTICAL INC-$1.3M -22.1%
New Positions
- AXSOME THERAPEUTICS INC.$6.9M
- KALVISTA PHARMACEUTICALS INC$5.6M
- ARROWHEAD PHARMACEUTICALS IN$3.5M
- VERA THERAPEUTICS INC$3.3M
- TRAVERE THERAPEUTICS INC$3.3M
Exited Positions
- NUVATION BIO INC$3.6M
- BRIDGEBIO PHARMA INC$2.8M
- UNITED THERAPEUTICS CORP DEL$2.7M
- BIOCRYST PHARMACEUTICALS INC$2.3M
- SYNDAX PHARMACEUTICALS INC$2.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $7.3M | 6.88% | 22,550 | SH |
| 2 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $6.9M | 6.56% | 41,000 | SH |
| 3 | PRAXIS PRECISION MEDICINES I Put | PRAX | 74006W207 | $6.6M | 6.25% | 20,500 | SH |
| 4 | XERIS BIOPHARMA HOLDINGS INC | XERS | 98422E103 | $5.9M | 5.63% | 1,025,000 | SH |
| 5 | KALVISTA PHARMACEUTICALS INC | KALV | 483497103 | $5.6M | 5.27% | 276,750 | SH |
| 6 | AMICUS THERAPEUTIC | FOLD | 03152W109 | $5.3M | 5.05% | 369,000 | SH |
| 7 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $4.6M | 4.39% | 82,000 | SH |
| 8 | VERASTEM INC | VSTM | 92337C203 | $4.3M | 4.11% | 820,000 | SH |
| 9 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $3.7M | 3.46% | 174,250 | SH |
| 10 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 04280A100 | $3.5M | 3.29% | 55,350 | SH |
| 11 | VAXCYTE INC | PCVX | 92243G108 | $3.3M | 3.16% | 57,400 | SH |
| 12 | VERA THERAPEUTICS INC | VERA | 92337R101 | $3.3M | 3.12% | 82,000 | SH |
| 13 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $3.3M | 3.11% | 110,700 | SH |
| 14 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $3.2M | 3.08% | 174,250 | SH |
| 15 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $2.9M | 2.72% | 1,230,000 | SH |
| 16 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $2.8M | 2.67% | 57,400 | SH |
| 17 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $2.7M | 2.59% | 123,000 | SH |
| 18 | ARDELYX INC | ARDX | 039697107 | $2.7M | 2.56% | 451,000 | SH |
| 19 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $2.2M | 2.10% | 82,000 | SH |
| 20 | GENMAB A/S | GMAB | 372303206 | $2.2M | 2.08% | 82,000 | SH |
| 21 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $2.1M | 2.03% | 102,500 | SH |
| 22 | CATALYST PHARMACEUTICALS INC | CPRX | 14888U101 | $2.0M | 1.92% | 82,000 | SH |
| 23 | SIONNA THERAPEUTICS INC | SION | 829401108 | $2.0M | 1.87% | 49,200 | SH |
| 24 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $1.9M | 1.76% | 142,000 | SH |
| 25 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $1.7M | 1.61% | 5,125 | SH |
| 26 | LIGAND PHARMACEUTICALS INC | LGND | 53220K504 | $1.6M | 1.55% | 8,200 | SH |
| 27 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $1.5M | 1.47% | 49,200 | SH |
| 28 | IMMATICS N.V | IMTX | N44445109 | $1.5M | 1.43% | 153,750 | SH |
| 29 | LEXICON PHARMACEUTICALS INC | LXRX | 528872302 | $1.4M | 1.33% | 902,000 | SH |
| 30 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $1.4M | 1.29% | 57,400 | SH |
| 31 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $1.3M | 1.23% | 102,500 | SH |
| 32 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $1.2M | 1.12% | 36,900 | SH |
| 33 | ANNEXON INC | ANNX | 03589W102 | $965.3K | 0.91% | 174,250 | SH |
| 34 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $819.7K | 0.78% | 24,600 | SH |
| 35 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $740.4K | 0.70% | 140,500 | SH |
| 36 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $698.3K | 0.66% | 10,250 | SH |
| 37 | GOSSAMER BIO INC | GOSS | 38341P102 | $269.4K | 0.26% | 820,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $105.6M | 37 | 0002111609-26-000002 |
| 2025-12-31 | 2026-02-17 | $87.5M | 38 | 0002111609-26-000001 |